<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5874081 - Therapeutic compositions and methods for inhibition and treatment of tumor ... - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Therapeutic compositions and methods for inhibition and treatment of tumor associated angiogenesis"><meta name="DC.contributor" content="Christopher Richard Parish" scheme="inventor"><meta name="DC.contributor" content="The Australia National University" scheme="assignee"><meta name="DC.date" content="1997-3-13" scheme="dateSubmitted"><meta name="DC.description" content="Antibodies, including monoclonal antibodies, specific for proliferating/angiogenic human endothelial cells such as human umbilical vein endothelial cells and human umbilical artery endothelial cells, and conjugates of these antibodies with a toxin material or label, are useful for inhibition of angiogenesis or for treatment of angiogenesis-dependent disease."><meta name="DC.date" content="1999-2-23" scheme="issued"><meta name="DC.relation" content="EP:0407122:A1" scheme="references"><meta name="DC.relation" content="EP:0457532:A1" scheme="references"><meta name="DC.relation" content="US:5512660" scheme="references"><meta name="DC.relation" content="US:5677181" scheme="references"><meta name="DC.relation" content="WO:1987001372:A1" scheme="references"><meta name="DC.relation" content="WO:1990012585:A1" scheme="references"><meta name="citation_reference" content="Biochemical &amp; Biophysical Research Communications, vol. 194, No. 3, issued 16 Aug., 1993, Kondo S et al; &quot;Significance of vascular endothelial growth factor/vascular permeability growth for solid tumor growth and its inhibition by the antibody&quot; pp. 1234-1240."><meta name="citation_reference" content="Biochemical &amp; Biophysical Research Communications, vol. 194, No. 3, issued 16 Aug., 1993, Kondo S et al; Significance of vascular endothelial growth factor/vascular permeability growth for solid tumor growth and its inhibition by the antibody pp. 1234 1240."><meta name="citation_reference" content="Brodsky, Eur. J. Immunol. 9:536, 1979."><meta name="citation_reference" content="Coleman et al., &quot;Hemostasis and Thrombosis&quot;, published 1994 by Hippincott Co. (Philadelphia) pp. 762-796."><meta name="citation_reference" content="Coleman et al., Hemostasis and Thrombosis , published 1994 by Hippincott Co. (Philadelphia) pp. 762 796."><meta name="citation_reference" content="Dillman, Ann. Int. Med. 111: 592, 1989."><meta name="citation_reference" content="Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature; vol. 90, pp. 8996 9000, Oct. 1993, Medical Sciences."><meta name="citation_reference" content="Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature; vol. 90, pp. 8996-9000, Oct. 1993, Medical Sciences."><meta name="citation_reference" content="Goldenberg et al. Ch. 13, in Immunoconjugate 1987 pp. 259 280 Oxford Univ. Press, NY."><meta name="citation_reference" content="Goldenberg et al. Ch. 13, in Immunoconjugate 1987 pp. 259-280 Oxford Univ. Press, NY."><meta name="citation_reference" content="Gougos, J. Immunol 141: 1925, 1988."><meta name="citation_reference" content="Hagemeier, Int. J. Cancer Res. 38: 481 488, 1986."><meta name="citation_reference" content="Hagemeier, Int. J. Cancer Res. 38: 481-488, 1986."><meta name="citation_reference" content="Harris, TIBTECH 11: 42 44, 1993."><meta name="citation_reference" content="Harris, TIBTECH 11: 42-44, 1993."><meta name="citation_reference" content="Haslow and Lane Antibodies: A Laboratory Manual CSH Lab. p. 287, 1988."><meta name="citation_reference" content="Hird, Genes and Cancer pp. 183 189, 1990 Wiley &amp; Son."><meta name="citation_reference" content="Hird, Genes and Cancer pp. 183-189, 1990 Wiley &amp; Son."><meta name="citation_reference" content="Matsuzaki, PNAS 86: 9911, 1989."><meta name="citation_reference" content="Philip E. Thorpe and Francis J. Burrows; &quot;Antibody-directed targeting of the vasculature of solid tumors&quot;; 1995; Breast Cancer Research and Treatment 36: 237-251."><meta name="citation_reference" content="Philip E. Thorpe and Francis J. Burrows; Antibody directed targeting of the vasculature of solid tumors ; 1995; Breast Cancer Research and Treatment 36: 237 251."><meta name="citation_reference" content="Press, J. Immunol. 141: 4410, 1988."><meta name="citation_reference" content="Roitt et al., &quot;Immunology&quot; published 1989 by Gowen Medical Publishing (NY &amp; London) p. 4.1-4.11."><meta name="citation_reference" content="Roitt et al., Immunology published 1989 by Gowen Medical Publishing (NY &amp; London) p. 4.1 4.11."><meta name="citation_reference" content="Tissue &amp; Cell, vol. 19, No. 4, 1987, M.E. Schelling et al; &quot;Immunochemical comparison of peptide angiogenic factors&quot; pp; 463-467."><meta name="citation_reference" content="Tissue &amp; Cell, vol. 19, No. 4, 1987, M.E. Schelling et al; Immunochemical comparison of peptide angiogenic factors pp; 463 467."><meta name="citation_reference" content="Vitetta, Science 238: 1098 1104, 1987."><meta name="citation_reference" content="Vitetta, Science 238: 1098-1104, 1987."><meta name="citation_reference" content="Wang, Angiogenesis EXS 61: 266 271, Apr. 22, 1992."><meta name="citation_reference" content="Wang, Angiogenesis EXS 61: 266-271, Apr. 22, 1992."><meta name="citation_patent_number" content="US:5874081"><meta name="citation_patent_application_number" content="US:08/815,933"><link rel="canonical" href="http://www.google.com/patents/US5874081"/><meta property="og:url" content="http://www.google.com/patents/US5874081"/><meta name="title" content="Patent US5874081 - Therapeutic compositions and methods for inhibition and treatment of tumor associated angiogenesis"/><meta name="description" content="Antibodies, including monoclonal antibodies, specific for proliferating/angiogenic human endothelial cells such as human umbilical vein endothelial cells and human umbilical artery endothelial cells, and conjugates of these antibodies with a toxin material or label, are useful for inhibition of angiogenesis or for treatment of angiogenesis-dependent disease."/><meta property="og:title" content="Patent US5874081 - Therapeutic compositions and methods for inhibition and treatment of tumor associated angiogenesis"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("HqPtU__MItCBogT9joCoAg"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("NZL"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("HqPtU__MItCBogT9joCoAg"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("NZL"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5874081?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5874081"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=5OFJBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5874081&amp;usg=AFQjCNG6ki8ZWOErMx6f8LhEf0rTuWmuVw" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5874081.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5874081.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5874081" style="display:none"><span itemprop="description">Antibodies, including monoclonal antibodies, specific for proliferating/angiogenic human endothelial cells such as human umbilical vein endothelial cells and human umbilical artery endothelial cells, and conjugates of these antibodies with a toxin material or label, are useful for inhibition of angiogenesis...</span><span itemprop="url">http://www.google.com/patents/US5874081?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5874081 - Therapeutic compositions and methods for inhibition and treatment of tumor associated angiogenesis</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5874081 - Therapeutic compositions and methods for inhibition and treatment of tumor associated angiogenesis" title="Patent US5874081 - Therapeutic compositions and methods for inhibition and treatment of tumor associated angiogenesis"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5874081 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/815,933</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Feb 23, 1999</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Mar 13, 1997</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Oct 29, 1992</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Lapsed</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2148244A1">CA2148244A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69333209D1">DE69333209D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69333209T2">DE69333209T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0669988A1">EP0669988A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0669988A4">EP0669988A4</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0669988B1">EP0669988B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0669988B2">EP0669988B2</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5677181">US5677181</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1994010331A1">WO1994010331A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08815933, </span><span class="patent-bibdata-value">815933, </span><span class="patent-bibdata-value">US 5874081 A, </span><span class="patent-bibdata-value">US 5874081A, </span><span class="patent-bibdata-value">US-A-5874081, </span><span class="patent-bibdata-value">US5874081 A, </span><span class="patent-bibdata-value">US5874081A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Christopher+Richard+Parish%22">Christopher Richard Parish</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22The+Australia+National+University%22">The Australia National University</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5874081.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5874081.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5874081.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (6),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (30),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (32),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (20),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (8)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5874081&usg=AFQjCNEZFNS-BwA6sr4MDXvQAM3RiRU-Hw">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5874081&usg=AFQjCNGIa4AwnnFbcJmyt2yJw67vKtxchA">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5874081A%26KC%3DA%26FT%3DD&usg=AFQjCNGzEc7esuhWIuGuENErBwKXgdNvQw">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54412669" lang="EN" load-source="patent-office">Therapeutic compositions and methods for inhibition and treatment of tumor associated angiogenesis</invention-title></span><br><span class="patent-number">US 5874081 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA37881837" lang="EN" load-source="patent-office"> <div class="abstract">Antibodies, including monoclonal antibodies, specific for proliferating/angiogenic human endothelial cells such as human umbilical vein endothelial cells and human umbilical artery endothelial cells, and conjugates of these antibodies with a toxin material or label, are useful for inhibition of angiogenesis or for treatment of angiogenesis-dependent disease.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(1)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5874081-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5874081-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(13)</span></span></div><div class="patent-text"><div mxw-id="PCLM5357726" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>I claim:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A therapeutic composition for inhibition of tumor associated angiogenesis or for treatment of tumor associated angiogenesis, selected from the group consisting essentially of:<div class="claim-text">i. an antibody which specifically binds proliferating human endothelial cells, said antibody binding proliferating human endothelial cells selected from the group consisting of proliferating human umbilical vein endothelial (HUVE) cells and human umbilical artery endothelial (HUAE) cells and not binding cells selected from the group consisting of non-proliferating HUVE cells and non-proliferating HUAE cells, and</div> <div class="claim-text">ii. an antibody-conjugate comprising an antibody and a conjugate material, said antibody of said antibody-conjugate being an antibody which specifically binds proliferating human endothelial cells, said antibody binding proliferating human endothelial cells selected from the group consisting of proliferating human umbilical vein endothelial (HUVE) cells and human umbilical artery endothelial (HUAE) cells and not binding cells selected from the group consisting of non-proliferating HUVE cells and non-proliferating HUAE cells, and said conjugate material being selected from the group consisting of a toxin material and a detectable label;</div> <div class="claim-text">together with a pharmaceutically acceptable carrier.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. A composition according to claim 1, wherein said antibody is a monoclonal antibody.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. A composition according to claim 1, wherein said antibody is conjugated to a cytotoxic material.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. A composition according to claim 3, wherein said cytotoxic material is selected from the group consisting of ricin A chain, diphtheria toxin, Pseudomonas exotoxin A and idarubicin.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. A composition according to claim 1, wherein said antibody is conjugated to a radioisotope label.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. A composition according to claim 5, wherein said radioisotope label is technetium-99m.</div>
    </div>
    </div> <div class="claim"> <div num="7" class="claim">
      <div class="claim-text">7. A method for inhibition of angiogenesis in a patient, said angiogenesis being associated with the growth of solid tumors, the method comprising administering to the patient an inhibition-effective amount of a therapeutic composition selected from the group consisting essentially of:<div class="claim-text">i. an antibody which specifically binds proliferating human endothelial cells, said antibody binding proliferating human endothelial cells selected from the group consisting of proliferating human umbilical vein endothelial (HUVE) cells and human umbilical artery endothelial (HUAE) cells and not binding cells selected from the group consisting of non-proliferating HUVE cells and non-proliferating HUAE cells, and</div> <div class="claim-text">ii. an antibody-conjugate comprising an antibody and a conjugate material, said antibody of said antibody-conjugate being an antibody which specifically binds proliferating human endothelial cells, said antibody binding proliferating human endothelial cells selected from the group consisting of proliferating human umbilical vein endothelial (HUVE) cells and human umbilical artery endothelial (HUAE) cells and not binding cells selected from the group consisting of non-proliferating HUVE cells and non-proliferating HUAE cells, and said conjugate material being selected from the group consisting of a toxin material and a detectable label;</div> <div class="claim-text">together with a pharmaceutically acceptable carrier.</div> </div>
    </div>
    </div> <div class="claim"> <div num="8" class="claim">
      <div class="claim-text">8. A method for treatment of tumor associated angiogenesis in a patient, which comprises administration to said patient of a therapeutic-effective amount of a therapeutic composition selected from the group consisting essentially of:<div class="claim-text">i. an antibody which specifically binds proliferating human endothelial cells, said antibody binding proliferating human endothelial cells selected from the group consisting of proliferating human umbilical vein endothelial (HUVE) cells and human umbilical artery endothelial (HUAE) cells and not binding cells selected from the group consisting of non-proliferating HUVE cells and non-proliferating HUAE cells, and</div> <div class="claim-text">ii. an antibody-conjugate comprising an antibody and a conjugate material, said antibody of said antibody-conjugate being an antibody which specifically binds proliferating human endothelial cells, said antibody binding proliferating human endothelial cells selected from the group consisting of proliferating human umbilical vein endothelial (HUVE) cells and human umbilical artery endothelial (HUAE) cells and not binding cells selected from the group consisting of non-proliferating HUVE cells and non-proliferating HUAE cells, and said conjugate material being selected from the group consisting of a toxin material and a detectable label;</div> <div class="claim-text">together with a pharmaceutically acceptable carrier.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. A method according to claim 7 or claim 8, wherein said antibody is a monoclonal antibody.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. A method according to claim 7 or claim 8, wherein said antibody is conjugated to a cytotoxic material.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. A method according to claim 10, wherein said cytotoxic material is selected from the group consisting of ricin A chain, diphtheria toxin, Pseudomonas exotoxin A and idarubicin.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. A method according to claim 7 or claim 8, wherein said antibody is conjugated to a radioisotope label.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" class="claim">
      <div class="claim-text">13. A method according to claim 12, wherein said radioisotope label is technetium-99m.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES67249671" lang="EN" load-source="patent-office" class="description">
    <p>This is a continuation of application Ser. No. 08/433,423, filed Jul. 3, 1995, now U.S. Pat. No. 5,677,181, which is a 371 of PCT/AU93/0058 filed Oct. 29, 1993.</p>
    <heading>FIELD OF THE INVENTION</heading> <p>This invention relates to angiogenesis inhibitory antibodies, and to the use thereof in the inhibition of angiogenesis, particularly angiogenesis associated with the growth of solid tumours, with proliferative retinopathies, and with certain inflammatory diseases.</p>
    <heading>BACKGROUND TO THE INVENTION</heading> <p>The circulatory system represents an extensive, branching, network of blood vessels which is essential for the supply of oxygen and nutrients to tissues and for the removal of byproducts of metabolism. In adults the development of new blood vessels or "angiogenesis" rarely occurs except during wound healing or as a result of a number of pathological situations termed "angiogenesis-dependent diseases".sup.(1,2). The most important of these is the angiogenesis associated with the growth of solid tumours and with proliferative retinopathies. Angiogenesis may also play an important role in rheumatoid arthritis and psoriasis.</p>
    <p>Angiogenesis inhibitors can, therefore, be of considerable value in the treatment of angiogenesis-dependent diseases. For example, in the case of solid tumours, the development of a blood supply is essential for the growth and survival of the tumour. Thus, inhibition of angiogenesis can provide a highly selective means of inducing tumour regression. Similarly, angiogenesis inhibitors may be used to prevent the blindness associated with proliferative diabetic retinopathy, one of the major complications of diabetes.</p>
    <p>In work leading to the present invention, monoclonal antibodies (mAbs) have been developed against proliferating/angiogenic human endothelial cells which can be used either to directly inhibit angiogenesis or to target cytotoxic drugs or radioisotope labels to sites of angiogenesis. Since angiogenesis does not occur in adults, except following tissue injury, such mAbs can be remarkably specific. Furthermore, unlike other lines of research which have produced cancer cell-specific mAbs to target cytotoxic drugs to tumours, the present invention is directed to producing mAbs against host antigens. This approach has the major advantage that generation of "resistant" variants of the tumour cannot occur and, in theory, one mAb could be used to treat all solid tumours. An additional advantage is that endothelial cells, by virtue of their vascular location, are very accessible to mAbs in the circulation.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>According to the present invention, there are provided antibodies, including monoclonal antibodies, specific for proliferating/angiogenic human endothelial cells.</p>
    <p>More particularly, the present invention provides antibodies, including monoclonal antibodies, specific for proliferating/angiogenic human umbilical vein endothelial cells (HUVEC) or human umbilical artery endothelial cells (HUAEC).</p>
    <p>This invention also extends to hybridoma cell lines producing the monoclonal antibodies as described above, which may be produced by methods well known to persons skilled in this field.</p>
    <p>As previously described, the antibodies in accordance with the invention may be used alone as an anti-angiogenesis agent in the treatment of angiogenesis-dependent disease in a patient.</p>
    <p>In another aspect, the present invention provides an antibody-conjugate comprising an antibody specific for proliferating/angiogenic human endothelial cells, having a toxin material or label conjugated thereto.</p>
    <p>The toxin material may, for example, be a cytotoxic drug or other cytotoxic material, however other toxin materials well known to persons skilled in this art may also be incorporated in the antibody-conjugate of this aspect of the invention. The label may be a radioisotope. Suitable toxin materials include, by way of example, ricin A chain, diphtheria toxin, Pseudomonas exotoxin A and idarubicin. A suitable radiolabel is technetium-99m. Coupling of various toxins to monoclonal antibodies may be effected by known methods.sup.(3,4,5,6). Similarly, the preparation of a conjugate with a radiolabel may use known methods.sup.(7).</p>
    <p>In yet another aspect, the invention provides a composition, particularly a therapeutic composition for inhibition of angiogenesis or for treatment of angiogenesis-dependent disease, comprising an antibody or antibody-conjugate as broadly described above, together with a pharmaceutically acceptable carrier or diluent.</p>
    <p>The present invention also extends to a method for inhibition of angiogenesis in a patient, for example angiogenesis associated with the growth of solid tumours or with proliferative retinopathies, which comprises administration to said patient of an inhibition-effective amount of an antibody or antibody-conjugate as broadly described above.</p>
    <p>In another aspect, this invention provides a method for treatment of angiogenesis-dependent disease in a patient, which comprises administration to said patient of a therapeutic-effective amount of an antibody or antibody-conjugate as broadly described above.</p>
    <p>Administration of the antibody or antibody-conjugate may be by any suitable route. Preferably, the administration to the patient is parenterally, for example, by injection.</p>
    <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p>In accordance with one embodiment of this invention, there have been developed monoclonal antibodies (mAbs) specific for proliferating/angiogenic endothelial cells. The major use of these mAbs is to simply inhibit angiogenesis, although if desired the mAbs can be used to target cytotoxic drugs or labels to angiogenic sites. In the case of tumours, this approach has the major advantages of tumour specificity, minimal side-effects, and little chance of "resistant" tumour variants arising. Furthermore, these mAbs provide a single therapeutic agent that can be used for all solid tumours, regardless of type and tissue location, and inhibition of angiogenesis in the solid tumours can result in tumour regression.</p>
    <p>The initial experimental approach has been to raise murine mAbs against proliferating/angiogenic human umbilical vein endothelial cells (HUVEC). Resultant mAbs have been screened initially for HUVEC reactivity and, subsequently, mAbs have been eliminated which react with other human cell lines, e.g. human melanoma cell lines. Finally, endothelial specific mAbs have been identified which fail to react with freshly isolated, non-proliferating/non-angiogenic human endothelial cells. Using this approach, it has been clearly established that mAbs can be obtained which are specific for proliferating/angiogenic human endothelial cells.</p>
    <heading>BRIEF DESCRIPTION OF THE DRAWING</heading> <p>FIG. 1 shows binding of mAbs to proliferating/angiogenic and resting (non-proliferating/non-angiogenic) human umbilical vein endothelial cells (HUVEC) as detected by immunofluorescence flow cytometry. CONT refers to HUVEC not incubated with mAbs, 20G5 is a HUVEC-specific mAb which reacts with both proliferating/angiogenic and resting HUVEC and 9B11 is a HUVEC-specific mAb which only reacts with proliferating/angiogenic HUVEC.</p>
    <p>Further details of the present invention will be apparent from the following detailed description of the production of endothelial specific mAbs in accordance with the invention.</p>
    <heading>EXAMPLE</heading> <p>A. Materials and Methods</p>
    <p>Cells</p>
    <p>Human umbilical vein (HUVEC) and artery (HUAEC) endothelial cells were prepared from human umbilical cords by the method of Jaffe.sup.(8) and cultured in Medium 199 supplemented with 20% foetal calf serum (FCS), L-glutamine, antibiotics, 130 ug/ml heparin and 1.2 mg/ml endothelial cell growth supplement (Sigma). HUVEC were used for mAb binding studies between passages 2 and 7. Human tumour cell lines (e.g. MM-170 melanoma, K562 erythroleukaemia) were cultured in RPMI-1640/10% FCS. Mononuclear cells (lymphocytes and monocytes) and neutrophils were simultaneously isolated from human peripheral blood by centrifugation of diluted blood on Polymorphprep™ (Nycomed. Pharma A.S., Oslo, Norway). Red cells and platelets were isolated by differential centrifugation from citrated human blood.</p>
    <p>Production of Hybridomas</p>
    <p>BALB/c mice were immunised, i.p., 3-4 times at 2--4 weekly intervals with 15×10<sup>6</sup> HUVEC in PBS and challenged 3 days prior to spleen cell removal with 15×10<sup>6</sup> HUVEC. A spleen cell suspension was prepared, fused with the myeloma NS1/1 AG4.1 and hybridomas grown up and cloned as described previously.sup.(9). To improve hybridoma growth and cloning efficiencies 10% endothelial cell conditioned medium (HUVEC or bovine corneal EC) was included in culture media.</p>
    <p>mAb Screening Assays.</p>
    <p>Initially hybridoma culture supernatants were tested for reactivity with HUVEC by immunofluorescence flow cytometry. Briefly, HUVEC (15×10<sup>4</sup>) were incubated (30 min, 4° C.) with undiluted hybridoma supernatant, washed and incubated with FITC-sheep F(ab')<sub>2</sub> anti-mouse lg(100 μg/ml). Following final washing HUVEC were examined for mAb binding by analysis on a Becton-Dickinson FACScan. Positive hybridoma supernatants were then screened on the human melanoma cell line MM-170 to eliminate non-endothelial specific mAbs. Endothelial specificity was further confirmed by screening mAbs on a panel of human tumour cell lines and human lymphocytes, monocytes, neutrophils, red cells and platelets. Finally, specificity for proliferating HUVEC was established by screening hybridoma supernatants on freshly isolated (non-cultured) HUVEC. Hybridomas which were positive on proliferating HUVEC but negative on freshly isolated HUVEC were cloned.sup.(9) for further study. A number of hybridomas (e.g. 20G5) which were endothelial-specific but not proliferation/angiogenesis-specific were also cloned.</p>
    <p>HUVEC Proliferation Assay</p>
    <p>Assays were performed in 96 well, flat bottom, microplates coated with 0.1% gelatin and containing 2.5×10<sup>4</sup> HUVEC/well in 150 μl of culture medium. After 24 hr culture cells were pulsed with <sup>3</sup> H-thymidine for a further 24 hr and <sup>3</sup> H-thymidine incorporation assessed in washed and harvested cells using a Titertek 530 cell harvester (Flow Labs). In mAb blocking experiments 50 μl/well of hybridoma supernatant was added at the commencement of the cultures with supernatant from a hybridoma which does not react with HUVEC being used as a negative control.</p>
    <p>B. Results</p>
    <p>Production of mAbs Specific for Proliferating/Angiogenic Endothelial Cells</p>
    <p>Table 1 shows that mAbs can be obtained which are specific for proliferating/angiogenic human endothelial cells.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 1______________________________________Production of Endothelial Specific Monoclonal Antibodies (mAbs).            NumberHybridomas         Fusion #1                       Fusion #2______________________________________Total screened     1196 .sup.                       660.sup.Proliferating HUVEC positive              811.sup. 276.sup.Proliferating HUVEC specific              541<sup>a</sup>                       102<sup>b</sup>Non-proliferating (resting)               25<sup>c</sup>                        17<sup>c</sup>HUVEC negative______________________________________ <sup>a</sup> Hybridomas not reactive with the human melanoma cell line MM170. <sup>b</sup> Hybridomas not reactive with human MM170 cell line, U937 monocytic cell line, lymphocytes, neutrophils, monocytes, red cells and platelets. <sup>c</sup> Hybridomas not reactive with endothelial cells freshly isolated from the human umbilical cord, i.e. endothelial cells "nonproliferating" or "resting". HUVEC = Human umbilical vein endothelial cells.</pre>
    
    <p>In the first fusion of 1196 hybridomas screened, 811 reacted with proliferating/angiogenic endothelial cells of which 541 were proliferating/angiogenic endothelial cell specific, i.e. failed to react with other proliferating human cell lines such as the human melanoma line MM-170. Of particular importance was the fact that 25 of the 541 hybridomas specific for proliferating/angiogenic human endothelial cells failed to react with non-proliferating/non-angiogenic (freshly isolated) endothelial cells. Thus, 4.6% of hybridomas produce mAbs which are proliferation/angiogenesis specific, a clear validation of the approach being used. A similar result was obtained in a second fusion where 16.6% of the HUVEC-specific mAbs were angiogenesis specific. A typical example of the results obtained with a proliferation/angiogenesis-specific (9B11) and a proliferation/angiogenesis non-specific (20G5) mAb is depicted in FIG. 1 as revealed by immunofluorescence flow cytometry.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 2______________________________________Reactivity Pattern of Some Cloned MonoclonalAntibodies Against Human Endothelial Cells      mAb Clones        9D9    12E5   20A5 14G11 21F10 20G5Human Cells  (IgM)  (IgM)  (IgM)                           (IgG1)                                 (IgM) (IgM)______________________________________Proliferating HUVEC        +      +      +    +     +     +Resting HUVEC        -      -      -    -     -     +Proliferating HUAEC        +      +      +    +     +     +K562 erythroleukaemia        -      -      +    +     +     -MM170 melanoma        -      ±   +    +     +     -PE.01 ovarian carcinoma        -      -      +    +     +     -COLO397 colonic        -      -      +    +     +     -carcinomaKJD keratinocyte        -      -      +    +     +     -carcinomaMT2 B lymphoma        -      -      +    +     +     +Molt 4 T lymphoma        -      -      +    +     +     +U937 (monocytic)        -      -      +    +     +     -Lymphocytes  -      -      +    -     -     +Neutrophils  -      ±   ± -     -     +Monocytes    -      +      +    ±  -     +RBC          -      -      -    -     -     -Platelets    ±   -      ± +     -     +Fibroblasts  -      -      +    ±  -     -______________________________________ HUVEC = human umbilical vein endothelial cells. HUAEC = human umbilical artery endothelial cells.</pre>
    
    <p>Table 2 presents detailed specificity analysis of six cloned mAbs, which were HUVEC reactive, as examples. One mAb (20G5) is a control which reacts with both resting and proliferating/angiogenic endothelial cells and is probably specific for the CD31 antigen. The remaining five mAbs react with proliferating/angiogenic but not resting endothelial cells. Three of these mAbs (10A5,14G11,21F10) react with many other proliferating cell types. The remaining two clones (9D9 and 12E5) exhibit considerable specificity for proliferating/angiogenic endothelial cells, 9D9 being the mAb with the greatest specificity, only exhibiting a weak reaction with platelets.</p>
    <p>The 9D9 mAb reacts with proliferating/angiogenic venular or arterial endothelial cells but not non-proliferating (resting) endothelial cells (Table 2). Subsequent studies showed that the 9D9 antigen appears on cultured HUVECS within 24 hr of culture and persists on HUVEC cultured for many passages, i.e. ten passages over a period of two months. The 9D9 antigen also appears on HUVEC whether they are cultured in 20% FCS+bovine growth supplement or 20% human serum, indicating that the 9D9 antigen is not derived from culture medium components.</p>
    <p>Effect of mAbs on Endothelial Cell Proliferation.</p>
    <p>When some of the proliferation-specific mAbs were added to proliferating HUVEC in vitro it was found that some of the mAbs could directly inhibit HUVEC proliferation. The results of a typical experiment are present in Table 3.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 3______________________________________Inhibition of HUVEC Proliferation by mAbs Specific forProliferating/Angiogenic Endothelial Cells.                  <sup>3</sup> H-Thymidine                  Incorporation*                             ResponsemAb    Specificity     (cpm)      % Control______________________________________9B9    Non-reactive    7779 ± 1420                             10020G5   HUVEC           6806 ± 1290                             87.51D5    Proliferating HUVEC**                  1256 ± 110                             16.18G4    Proliferating HUVEC**                  1857 ± 38                             23.916C6   Proliferating HUVEC**                  1767 ± 175                             22.719D4   Proliferating HUVEC**                  7530 ± 753                             96.8______________________________________ *HUVEC cultured in proliferaion assay with dialyzed hybridoma supernatant containing mAbs. Proliferation measured 24-48 hr following culture initiation and represents mean ± standard error of three determinations. **mAbs only react with proliferating/angiogenic (not resting) HUVEC.</pre>
    
    <p>Of the four proliferation/angiogenesis-specific mAbs tested, three (1D5,8G4 and 16C6) inhibited HUVEC proliferation by approx. 75-85% as measured by <sup>3</sup> H-thymidine incorporation. In contrast, one proliferation/angiogenesis-specific mAb (19D4) and 20G5, a mAb which reacts with both proliferating and non-proliferating HUVEC, had no significant effect on HUVEC proliferation. The mAb 9B9, which does not react with HUVEC, was used as the negative control in this experiment.</p>
    <p>These data strongly suggest that some of the proliferation/angiogenesis-specific mAbs may directly inhibit angiogenesis, thus bypassing the need for cytotoxic drug-mAb conjugates. It should be emphasised that the data presented in Table 2 were obtained with hybridoma supernatants and not with purified and concentrated mAb preparations.</p>
    <heading>REFERENCES</heading> <p>1. Folkman, J. Adv.Cancer Res. 43, 175-203 (1985).</p>
    <p>2. Folkman, J. and Klagsbrun, M. Science 235, 442-447 (1987).</p>
    <p>3. Bridges, S., Longo, D. L. and Youle, R. J. Methods Enzymol. 178, 356-368 (1989).</p>
    <p>4. Colombatti, M., Dell'Arciprete, L., Rappouli, R. and Tridente, G. Methods Enzymol. 178, 404-422 (1989).</p>
    <p>5. Kondo, T., Fitzgerald, D., Chaudhary, V. K., Adhya, S. and Pastan, I. J.Bio.Chem. 263, 9470-9475 (1988).</p>
    <p>6. Pietersz, G. A., Smyth, M. J. and McKenzie, I. F. C. Cancer Res. 48, 926-931 (1988).</p>
    <p>7. Lee, R-T., Milner, L. J., Boniface, G. R., Bautovich, G. J., Weedon, A. R. J., Bundesen, P. G., Rylatt, D. B. and Walker, K. Z. Immunol. Cell Biol. 70, 173-179 (1992).</p>
    <p>8. Jaffe, E. A. In "Biology of Endothelial Cells", E. A. Jaffe, ed., Martinus-Nijhoff, The Hague (1984).</p>
    <p>9. Goding, J. W. J.Immunol. Methods 39, 285-308 (1980).</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5512660">US5512660</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 10, 1994</td><td class="patent-data-table-td patent-date-value">Apr 30, 1996</td><td class="patent-data-table-td ">Dana Farber Cancer Institute, Inc.</td><td class="patent-data-table-td ">Purified ICAM-2 and fragment thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5677181">US5677181</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 29, 1993</td><td class="patent-data-table-td patent-date-value">Oct 14, 1997</td><td class="patent-data-table-td ">The Australian National University</td><td class="patent-data-table-td ">Antitumor, antiinflammatory agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0407122A1?cl=en">EP0407122A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 2, 1990</td><td class="patent-data-table-td patent-date-value">Jan 9, 1991</td><td class="patent-data-table-td ">Repligen Corporation</td><td class="patent-data-table-td ">Novel modified PF4 compositions and methods of use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0457532A1?cl=en">EP0457532A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 13, 1991</td><td class="patent-data-table-td patent-date-value">Nov 21, 1991</td><td class="patent-data-table-td ">FIDIA S.p.A.</td><td class="patent-data-table-td ">Monoclonal antibody which inhibits the biological action of platelet factor 4</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1987001372A1?cl=en">WO1987001372A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 16, 1986</td><td class="patent-data-table-td patent-date-value">Mar 12, 1987</td><td class="patent-data-table-td ">Harvard College</td><td class="patent-data-table-td ">cDNA AND GENE FOR HUMAN ANGIOGENIN (ANGIOGENESIS FACTOR) AND METHODS OF EXPRESSION</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1990012585A1?cl=en">WO1990012585A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 9, 1990</td><td class="patent-data-table-td patent-date-value">Oct 11, 1990</td><td class="patent-data-table-td ">Oncogen</td><td class="patent-data-table-td ">Methods for controlling human endothelial cell proliferation and effector functions using oncostatin m</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Biochemical &amp; Biophysical Research Communications, vol. 194, No. 3, issued 16 Aug., 1993, Kondo S et al; "<a href='http://scholar.google.com/scholar?q="Significance+of+vascular+endothelial+growth+factor%2Fvascular+permeability+growth+for+solid+tumor+growth+and+its+inhibition+by+the+antibody"'>Significance of vascular endothelial growth factor/vascular permeability growth for solid tumor growth and its inhibition by the antibody</a>" pp. 1234-1240.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Biochemical &amp; Biophysical Research Communications, vol. 194, No. 3, issued 16 Aug., 1993, Kondo S et al; Significance of vascular endothelial growth factor/vascular permeability growth for solid tumor growth and its inhibition by the antibody pp. 1234 1240.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Brodsky, Eur. J. Immunol. 9:536, 1979.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Coleman et al., "<a href='http://scholar.google.com/scholar?q="Hemostasis+and+Thrombosis"'>Hemostasis and Thrombosis</a>", published 1994 by Hippincott Co. (Philadelphia) pp. 762-796.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Coleman et al., Hemostasis and Thrombosis , published 1994 by Hippincott Co. (Philadelphia) pp. 762 796.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Dillman, Ann. Int. Med. 111: 592, 1989.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature; vol. 90, pp. 8996 9000, Oct. 1993, Medical Sciences.</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature; vol. 90, pp. 8996-9000, Oct. 1993, Medical Sciences.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Goldenberg et al. Ch. 13, in Immunoconjugate 1987 pp. 259 280 Oxford Univ. Press, NY.</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Goldenberg et al. Ch. 13, in Immunoconjugate 1987 pp. 259-280 Oxford Univ. Press, NY.</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Gougos, J. Immunol 141: 1925, 1988.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hagemeier, Int. J. Cancer Res. 38: 481 488, 1986.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hagemeier, Int. J. Cancer Res. 38: 481-488, 1986.</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Harris, TIBTECH 11: 42 44, 1993.</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Harris, TIBTECH 11: 42-44, 1993.</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Haslow and Lane Antibodies: A Laboratory Manual CSH Lab. p. 287, 1988.</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hird, Genes and Cancer pp. 183 189, 1990 Wiley &amp; Son.</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hird, Genes and Cancer pp. 183-189, 1990 Wiley &amp; Son.</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Matsuzaki, PNAS 86: 9911, 1989.</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Philip E. Thorpe and Francis J. Burrows; "<a href='http://scholar.google.com/scholar?q="Antibody-directed+targeting+of+the+vasculature+of+solid+tumors"'>Antibody-directed targeting of the vasculature of solid tumors</a>"; 1995; Breast Cancer Research and Treatment 36: 237-251.</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Philip E. Thorpe and Francis J. Burrows; Antibody directed targeting of the vasculature of solid tumors ; 1995; Breast Cancer Research and Treatment 36: 237 251.</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Press, J. Immunol. 141: 4410, 1988.</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Roitt et al., "<a href='http://scholar.google.com/scholar?q="Immunology"'>Immunology</a>" published 1989 by Gowen Medical Publishing (NY &amp; London) p. 4.1-4.11.</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Roitt et al., Immunology published 1989 by Gowen Medical Publishing (NY &amp; London) p. 4.1 4.11.</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tissue &amp; Cell, vol. 19, No. 4, 1987, M.E. Schelling et al; "<a href='http://scholar.google.com/scholar?q="Immunochemical+comparison+of+peptide+angiogenic+factors"'>Immunochemical comparison of peptide angiogenic factors</a>" pp; 463-467.</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Tissue &amp; Cell, vol. 19, No. 4, 1987, M.E. Schelling et al; Immunochemical comparison of peptide angiogenic factors pp; 463 467.</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Vitetta, Science 238: 1098 1104, 1987.</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Vitetta, Science 238: 1098-1104, 1987.</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Wang, Angiogenesis EXS 61: 266 271, Apr. 22, 1992.</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wang, Angiogenesis EXS 61: 266-271, Apr. 22, 1992.</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6261535">US6261535</a></td><td class="patent-data-table-td patent-date-value">Dec 8, 1998</td><td class="patent-data-table-td patent-date-value">Jul 17, 2001</td><td class="patent-data-table-td ">The University Of Texas System Board Of Regents</td><td class="patent-data-table-td ">Images of tumors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6342219">US6342219</a></td><td class="patent-data-table-td patent-date-value">Apr 28, 2000</td><td class="patent-data-table-td patent-date-value">Jan 29, 2002</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">As anti-angiogenic and in tumor therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6342221">US6342221</a></td><td class="patent-data-table-td patent-date-value">Apr 28, 2000</td><td class="patent-data-table-td patent-date-value">Jan 29, 2002</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Antibody conjugate compositions for selectively inhibiting VEGF</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6416758">US6416758</a></td><td class="patent-data-table-td patent-date-value">Apr 28, 2000</td><td class="patent-data-table-td patent-date-value">Jul 9, 2002</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texax System</td><td class="patent-data-table-td ">Antibody conjugate kits for selectively inhibiting VEGF</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6451312">US6451312</a></td><td class="patent-data-table-td patent-date-value">Jul 20, 1999</td><td class="patent-data-table-td patent-date-value">Sep 17, 2002</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Diagnosis, imaging; induction of endothelial cell surface antigens</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6524583">US6524583</a></td><td class="patent-data-table-td patent-date-value">Apr 28, 2000</td><td class="patent-data-table-td patent-date-value">Feb 25, 2003</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Inhibit angiogenesis and induce tumor regression, and have improved safety due to their specificity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6676941">US6676941</a></td><td class="patent-data-table-td patent-date-value">Nov 30, 2001</td><td class="patent-data-table-td patent-date-value">Jan 13, 2004</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">For inhibiting angiogenesis and induce tumor regression; cancer therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6703020">US6703020</a></td><td class="patent-data-table-td patent-date-value">Apr 28, 2000</td><td class="patent-data-table-td patent-date-value">Mar 9, 2004</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Antibody conjugate methods for selectively inhibiting VEGF</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6887468">US6887468</a></td><td class="patent-data-table-td patent-date-value">Apr 28, 2000</td><td class="patent-data-table-td patent-date-value">May 3, 2005</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Antibody kits for selectively inhibiting VEGF</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6887473">US6887473</a></td><td class="patent-data-table-td patent-date-value">May 19, 1998</td><td class="patent-data-table-td patent-date-value">May 3, 2005</td><td class="patent-data-table-td ">The Scripps Research Institute</td><td class="patent-data-table-td ">Administering as antitumor, antimetastasis, antiinflammatory, or anticarcinogenic agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7056506">US7056506</a></td><td class="patent-data-table-td patent-date-value">Jul 5, 2002</td><td class="patent-data-table-td patent-date-value">Jun 6, 2006</td><td class="patent-data-table-td ">The Regents Of The University Of California</td><td class="patent-data-table-td ">Methods for detecting and inhibiting angiogenesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7056509">US7056509</a></td><td class="patent-data-table-td patent-date-value">Feb 24, 2003</td><td class="patent-data-table-td patent-date-value">Jun 6, 2006</td><td class="patent-data-table-td ">Board Of Regents The University Of Texas System</td><td class="patent-data-table-td ">Monoclonal antibodies used as antagonists vascular endothelial growth factors (VEGF); angiogenesis inhibitors; antitumor agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7067109">US7067109</a></td><td class="patent-data-table-td patent-date-value">Jul 12, 1999</td><td class="patent-data-table-td patent-date-value">Jun 27, 2006</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Phosphatidyl serine, cephalins binding to surfaces of tumor blood vessels; induce thrombosis, necrosis in tumor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7112317">US7112317</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2003</td><td class="patent-data-table-td patent-date-value">Sep 26, 2006</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Administering a targeting agent operatively attached to a therapeutic agent; the targeting agent recognizes and binds to a tumor-associated endothelial cell marker.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7125541">US7125541</a></td><td class="patent-data-table-td patent-date-value">Dec 14, 2000</td><td class="patent-data-table-td patent-date-value">Oct 24, 2006</td><td class="patent-data-table-td ">The University Of Texas System Board Of Regents</td><td class="patent-data-table-td ">Administering targeting agent operatively attached to a therapeutic agent, and wherein the targeting agent recognizes and binds to a tumor-associated endothelial cell marker</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7276589">US7276589</a></td><td class="patent-data-table-td patent-date-value">Nov 26, 2003</td><td class="patent-data-table-td patent-date-value">Oct 2, 2007</td><td class="patent-data-table-td ">Pdl Biopharma, Inc.</td><td class="patent-data-table-td ">Using immunoaffinity matrix to isolate immunoglobulin angiogenesis inhibitors for use in treatment of vision, inflammatory and cell proliferative disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7285268">US7285268</a></td><td class="patent-data-table-td patent-date-value">Apr 23, 2004</td><td class="patent-data-table-td patent-date-value">Oct 23, 2007</td><td class="patent-data-table-td ">Pdl Biopharma, Inc.</td><td class="patent-data-table-td ">Immunoglobulin angiogenesis inhibitors for use in treatment of vision, inflammatory and cell proliferative disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7311911">US7311911</a></td><td class="patent-data-table-td patent-date-value">Oct 14, 2003</td><td class="patent-data-table-td patent-date-value">Dec 25, 2007</td><td class="patent-data-table-td ">The Regents Of The University Of California</td><td class="patent-data-table-td ">Methods for inhibiting angiogenesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7354586">US7354586</a></td><td class="patent-data-table-td patent-date-value">Jul 15, 2004</td><td class="patent-data-table-td patent-date-value">Apr 8, 2008</td><td class="patent-data-table-td ">The Scripps Research Institute</td><td class="patent-data-table-td ">Treating arthritis by administering a therapeutically effective amount of an antibody immunospecific for av beta 3; antiarthritic agents;anticarcinogenic agents; antitumor agents; antimetastasis agents; antiinflammatory agents; antibody does not immunoreact with integrins other than av beta 3</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7422738">US7422738</a></td><td class="patent-data-table-td patent-date-value">Nov 30, 2001</td><td class="patent-data-table-td patent-date-value">Sep 9, 2008</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Combined cancer treatment methods using antibodies to aminophospholipids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7550141">US7550141</a></td><td class="patent-data-table-td patent-date-value">Nov 12, 2004</td><td class="patent-data-table-td patent-date-value">Jun 23, 2009</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7595051">US7595051</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 2007</td><td class="patent-data-table-td patent-date-value">Sep 29, 2009</td><td class="patent-data-table-td ">The Scripps Research Institute</td><td class="patent-data-table-td ">Methods of treating neovascular glaucoma, macular degeneration and capillary proliferation with alphavbeta3-specific antibodies</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7662384">US7662384</a></td><td class="patent-data-table-td patent-date-value">Mar 24, 2005</td><td class="patent-data-table-td patent-date-value">Feb 16, 2010</td><td class="patent-data-table-td ">Facet Biotech Corporation</td><td class="patent-data-table-td ">Use of anti-α5β1 antibodies to inhibit cancer cell proliferation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7776585">US7776585</a></td><td class="patent-data-table-td patent-date-value">Aug 17, 2007</td><td class="patent-data-table-td patent-date-value">Aug 17, 2010</td><td class="patent-data-table-td ">Facet Biotech Corporation</td><td class="patent-data-table-td ">Expression vector comprising nucleotide sequences coding integrin specific immunoglobulin for use as neovascularization inhibitor; antitumor agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7790860">US7790860</a></td><td class="patent-data-table-td patent-date-value">Feb 13, 2009</td><td class="patent-data-table-td patent-date-value">Sep 7, 2010</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Targeting and imaging tumor vasculature using conjugates that bind to aminophospholipids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7879987">US7879987</a></td><td class="patent-data-table-td patent-date-value">Aug 17, 2007</td><td class="patent-data-table-td patent-date-value">Feb 1, 2011</td><td class="patent-data-table-td ">Facet Biotech Corporation</td><td class="patent-data-table-td ">Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7897148">US7897148</a></td><td class="patent-data-table-td patent-date-value">Sep 7, 2007</td><td class="patent-data-table-td patent-date-value">Mar 1, 2011</td><td class="patent-data-table-td ">Abbott Biotherapeutics Corp.</td><td class="patent-data-table-td ">Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8017116">US8017116</a></td><td class="patent-data-table-td patent-date-value">Aug 17, 2007</td><td class="patent-data-table-td patent-date-value">Sep 13, 2011</td><td class="patent-data-table-td ">Abbott Biotherapeutics Corp.</td><td class="patent-data-table-td ">Using growth factor specific immunoglobulin as therapeutic in treating eye tissue injury</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8309084">US8309084</a></td><td class="patent-data-table-td patent-date-value">Jan 19, 2011</td><td class="patent-data-table-td patent-date-value">Nov 13, 2012</td><td class="patent-data-table-td ">Abbott Biotherapeutics Corp.</td><td class="patent-data-table-td ">Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8454958">US8454958</a></td><td class="patent-data-table-td patent-date-value">Dec 7, 2011</td><td class="patent-data-table-td patent-date-value">Jun 4, 2013</td><td class="patent-data-table-td ">The Regents Of The University Of California</td><td class="patent-data-table-td ">Methods for detecting and inhibiting angiogenesis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8486391">US8486391</a></td><td class="patent-data-table-td patent-date-value">Jan 10, 2006</td><td class="patent-data-table-td patent-date-value">Jul 16, 2013</td><td class="patent-data-table-td ">Board Of Regents, University Of Texas System</td><td class="patent-data-table-td ">Cancer treatment kits using antibodies to aminophospholipids</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8709430">US8709430</a></td><td class="patent-data-table-td patent-date-value">Oct 19, 2005</td><td class="patent-data-table-td patent-date-value">Apr 29, 2014</td><td class="patent-data-table-td ">Board Of Regents, The University Of Texas System</td><td class="patent-data-table-td ">Cancer treatment kits comprising therapeutic antibody conjugates that bind to aminophospholipids</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S130100">424/130.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S178100">424/178.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S183100">424/183.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S152100">424/152.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S141100">424/141.1</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc424/defs424.htm&usg=AFQjCNH9_TEmt6LWxUKihruum311Bzz0Rg#C424S181100">424/181.1</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0005100000">C12N5/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12P0021080000">C12P21/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0035000000">A61P35/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0039395000">A61K39/395</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C12N0015020000">C12N15/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0016280000">C07K16/28</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047480000">A61K47/48</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038000000">A61K38/00</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/00">A61K38/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/48561">A61K47/48561</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K16/28">C07K16/28</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=5OFJBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K2317/73">C07K2317/73</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07K16/28</span>, <span class="nested-value">A61K47/48T4B28</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Apr 12, 2011</td><td class="patent-data-table-td ">FP</td><td class="patent-data-table-td ">Expired due to failure to pay maintenance fee</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20110223</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 23, 2011</td><td class="patent-data-table-td ">LAPS</td><td class="patent-data-table-td ">Lapse for failure to pay maintenance fees</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 27, 2010</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 17, 2009</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 1-13 IS CONFIRMED. NEW CLAIMS 14-16 CANCELLED.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 21, 2007</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20070711</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 4, 2006</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 10, 2002</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 22, 2002</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U103Ce9ONpyavjxjamJNrB6z6HnVA\u0026id=5OFJBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0WXcJ8AsDOD4muGaChNVbczLrDmQ\u0026id=5OFJBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U1fQHQdC8TATDvh1XpS0JaMc_LscQ","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Therapeutic_compositions_and_methods_for.pdf?id=5OFJBAABERAJ\u0026output=pdf\u0026sig=ACfU3U3YVtwQhOpbncSInxDVc6GDY1lZyQ"},"sample_url":"http://www.google.com/patents/reader?id=5OFJBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>